Biogen Looks To Bulk Up Rare Disease Portfolio With $7.3 Billion Acquisition
Biogen will buy Reata Pharmaceuticals and its Friedreich's ataxia drug in a $7.3 billion deal. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 28, 2023 Category: Pharmaceuticals Authors: Mary Whitfill Roeloffs, Forbes Staff Tags: Business /business Innovation /innovation Healthcare /healthcare Breaking breaking-news topline Source Type: news
First Treatment Approved for Rare Neurodegenerative Disorder
(MedPage Today) -- The FDA approved omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia in patients ages 16 and older, making it the first approved treatment for this rare progressive neurodegenerative disorder, the agency said Tuesday... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 1, 2023 Category: American Health Source Type: news
FDA OKs First Treatment for Friedreich's Ataxia FDA OKs First Treatment for Friedreich's Ataxia
Omaveloxolone has been approved for adults and adolescents aged 16 and older who have the ultra-rare neurodegenerative disorder Friedreich ' s ataxia.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 1, 2023 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Spinal Cord MRI Reveals Clues to Pathology in Friedreich's Ataxia Spinal Cord MRI Reveals Clues to Pathology in Friedreich's Ataxia
Imaging data sheds light on the pathology behind this genetic, neurodegenerative disorder.First Look (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - April 27, 2022 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Friedreich's Ataxia Treatment Shows Extended Benefit Friedreich's Ataxia Treatment Shows Extended Benefit
A treatment that protects against inflammation may also help in slowing progression of Friedreich ' s ataxia out to more than 2 years, a new phase 2 trial suggests.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 21, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
PTC Therapeutics Announces Initiation of Global Phase 3 Clinical Trial to Evaluate Vatiquinone in Friedreich Ataxia
Third trial initiated in 2020 from compounds identified from PTC's Bio-e platform
SOUTH PLAINFIELD, N.J., Nov. 30, 2020 -- (Healthcare Sales & Marketing Network) -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the initiation of the registrati... Biopharmaceuticals PTC Therapeutics, vatiquinone, Friedreich ataxia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 30, 2020 Category: Pharmaceuticals Source Type: news
Gene therapy corrects the cardiac effects of Friedreich's ataxia
(Mary Ann Liebert, Inc./Genetic Engineering News) Gene therapy was successfully used to overcome the cardiac effects of Freidreich's ataxia (FA) in a mouse model of the disease (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 18, 2020 Category: International Medicine & Public Health Source Type: news
Exercise offers 'profound' benefits for Friedreich's ataxia, research suggests
(University of Virginia Health System) Well-timed exercise programs may slow the progression of Friedreich's ataxia, which robs patients of their ability to walk, new research suggests. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - June 16, 2020 Category: International Medicine & Public Health Source Type: news
Friedreich's Ataxia Syndrome
Title: Friedreich's Ataxia SyndromeCategory: Diseases and ConditionsCreated: 2/25/2020 12:00:00 AMLast Editorial Review: 2/25/2020 12:00:00 AM (Source: MedicineNet Kids Health General)
Source: MedicineNet Kids Health General - February 25, 2020 Category: Pediatrics Source Type: news
Health-related quality of life and depressive symptoms in Friedreich ataxia - P érez-Flores J, Hernández-Torres A, Montón F, Nieto A.
PURPOSE: Friedreich ataxia (FRDA) is a chronic, progressive and highly disabling cerebellar degenerative disease. Despite this, little attention has been paid to the health-related quality of life (HRQOL) in this disease. The aim of the present study was t... (Source: SafetyLit)
Source: SafetyLit - October 1, 2019 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
REGENXBIO Announces New License Agreement with Pfizer for the Treatment of Friedreich's Ataxia Using NAV(R) AAV9 Vector
ROCKVILLE, Md., July 31, 2019 -- (Healthcare Sales & Marketing Network) -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV T... Biopharmaceuticals, Neurology, Licensing REGENXBIO, Pfizer, Friedreich's ataxia, movement disorder (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 31, 2019 Category: Pharmaceuticals Source Type: news
Canine companion helps man with rare genetic disorder that leaves him confined to a wheelchair
Matthew Lafleur, 33, from Opelousas, Louisiana, was diagnosed with Friedreich's Ataxia when he was 11 years old. He now gets around with the help of his new service dog named Zeego. (Source: the Mail online | Health)
Source: the Mail online | Health - July 4, 2019 Category: Consumer Health News Source Type: news
Woman who thought she was clumsy is diagnosed with degenerative condition and now needs a walker
Madelyn Frederick, 20, from Dallas, Texas, was diagnosed in March 2013 with Friedreich's Ataxia, a rare genetic disease that affects the nervous system and causes a progressive loss of movement. (Source: the Mail online | Health)
Source: the Mail online | Health - May 15, 2019 Category: Consumer Health News Source Type: news
Woman who called herself 'clumsy' discovers she has a genetic disorder that makes her trip
Kelly Barendt, 26, from Strongsville, Ohio, was diagnosed at age 18 which had Friedreich's Ataxia, a rare genetic disease that affects the nervous system and causes a progressive loss of movement. (Source: the Mail online | Health)
Source: the Mail online | Health - April 30, 2019 Category: Consumer Health News Source Type: news
C-Path, FARA launch Friedreich's Ataxia Clinical Database for Development of Treatments
(Critical Path Institute (C-Path)) C-Path's Data Collaboration Center and FARA announced the launch of the Friedreich's Ataxia Integrated Clinical Database. The platform will enable collaborative research and data sharing to support the understanding of natural history, biomarkers and clinical endpoints, and promote research into clinical trial design in Friedreich's ataxia. The organizations hope to enable the development of tools that will help design and interpret efficient clinical trials -- leading to effective treatments for FA as soon as possible. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 27, 2019 Category: International Medicine & Public Health Source Type: news
